Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Summary

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.

Timeline

Start

2024-08-13

Primary completion

2027-05-31

Completion

2027-11-30

Drugs

Indications